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Abstract The aim of the present study was to investigate
the effect of sorafenib and quercetin on the induction of
apoptosis and autophagy in human anaplastic astrocytoma
(MOGGCCM) and glioblastoma multiforme (T98G) cell
lines. In MOGGCCM cells, sorafenib initiated mainly
apoptosis, mediated by the mitochondrial pathway with
mitochondrial membrane permeabilization, cytochrome c
release to the cytoplasm, and activation of caspase 9 and 3.
Additional incubation with quercetin potentiated the pro-
apoptotic properties of sorafenib. In T98G cells, autophagy
was observed most frequently after the sorafenib treatment.
It was accompanied by increased beclin 1 and LC3II
expression. Administration of quercetin after the sorafenib
treatment resulted in an increased number of autophagic
cells. After simultaneous drug application, the level of
autophagy was lower in favour of apoptosis. Inhibition of
heat shock proteins expression by specific small interfering
RNA significantly increased the sensitivity of both the cell
lines to induction of apoptosis, but not autophagy. We
demonstrated for the first time that sorafenib and quercetin
are very effective programmed cell death inducers in T98G
and MOGGCCM cells, especially in cells with blocked
expression of heat shock proteins.
Keywords Sorafenib  Quercetin  Apoptosis 
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Introduction
Malignant gliomas are the most prevalent primary brain
tumours in adults, exhibiting a high rate of cell prolifera-
tion and migration activities. The major group is repre-
sented by anaplastic astrocytoma (AA, WHO grade III) and
glioblastoma multiforme (GBM, WHO grade IV). Despite
tremendous efforts in improvement of therapeutics, such as
surgery, radiotherapy and chemotherapy, the clinical out-
come of gliomas remains dismaying. The median survival
in patients with anaplastic astrocytoma is about 30 months,
while with glioblastoma multiforme it is less than
15 months under standard care treatment. Therefore, there
is an urgent need for new treatments based on a better
understanding of the molecular basis of malignant pro-
gression of gliomas (Kleihues et al. 2002; Ohgaki and
Kleihues 2005; Omuro et al. 2007).
It has been proven that upregulation of the Ras–Raf–
MEK–ERK pathway takes part in amplification of mito-
genic stimuli and promotion of cellular proliferation of
malignant gliomas. Therefore, downregulation of this sig-
nal transmission may be a valuable therapy for glioma
patients leading to apoptosis or autophagy induction (Lo
J. Jakubowicz-Gil (&)  D. Ba˛dziul
Department of Comparative Anatomy and Anthropology, Maria
Curie-Skłodowska University, Akademicka 19, 20-033 Lublin,
Poland
e-mail: jjgil@poczta.umcs.lublin.pl; dorota.badziul@wp.pl
E. Langner  W. Rzeski
Department of Medical Biology, Institute of Agricultural





1st Department of Gynaecology, University School of Medicine,
Staszica 16, 20-081 Lublin, Poland
e-mail: iwonawertel@wp.pl
W. Rzeski
Department of Immunology and Virology, Maria Curie-
Skłodowska University, Akademicka 19, 20-033 Lublin, Poland
123
Neurotox Res (2014) 26:64–77
DOI 10.1007/s12640-013-9452-x
2010). A promising candidate for such an action is so-
rafenib—a small-molecule multikinase inhibitor that was
originally developed as an inhibitor of Raf kinase, an
essential serine/threonine kinase constituent of the mito-
gen-activated protein kinase (MAPK) pathway. Intracranial
application of sorafenib caused inhibition of cell prolifer-
ation, reduction of angiogenesis, and induction of autoph-
agy and apoptosis of glioma cells. Systemic administration
of sorafenib was well tolerated and the drug crossed the
blood–brain barrier effectively (Hahn and Stadler 2006;
Sieglin et al. 2010; Wilhelm et al. 2004). Unfortunately, its
use in the clinical treatment of patients with malignant
gliomas has yielded disappointing results in some cases
(Nabors et al. 2011; Sieglin et al. 2010; Yang et al. 2010).
Nevertheless, the ability of sorafenib to inhibit tumour cell
proliferation suggests that it may be useful in combination
with other therapeutic agents. It is well known that natural
active compounds may act in synergy with drugs used in
clinical applications. One of them is quercetin (3,30,40,5,7-
pentahydroxyflavone), a natural flavonoid found in a broad
range of fruits and vegetables. It has multiple biological,
pharmacological and medical applications and is one of the
most potent antioxidants. Quercetin facilitates apoptosis of
tumour cells by caspase 3 and caspase 9 activation and
cytochrome c release. It is a well-known inhibitor of
expression of heat shock proteins (Hsps) (Braganhol et al.
2006; Hosokawa et al. 1992; Ramos 2007; Russo 2007;
Schu¨ltke et al. 2005).
Therefore, the aim of our studies was to investigate the
effect of sorafenib applied alone or in combination with
quercetin on induction of apoptosis and autophagy in
human glioblastoma multiforme T98G and anaplastic
astrocytoma MOGGCCM cell lines. We analysed the typ-
ical morphology for programmed cell death as well as the
molecular mechanism underlying these processes based on
the expression of Hsp27, Hsp72, cytochrome c, LC3, beclin
1, and Ras and Raf proteins and the activity of caspase 3,
caspase 8 and caspase 9. Additionally, we studied the
sensitivity of MOGGCCM and T98G cell lines with
blocked Hsp27 and Hsp72 expression to programmed cell
death induction upon combined drug treatment.
Materials and Methods
Cells and Culture Conditions
Human glioblastoma multiforme cells (T98G, European
Collection of Cell Cultures) and human anaplastic astro-
cytoma cells (MOGGCCM, European Collection of Cell
Cultures) were grown in a 3:1 mixture of Dulbecco’s
Modified Eagle Medium (DMEM) and Ham’s nutrient
mixture F-12 (Sigma) supplemented with 10 % foetal
bovine serum (Sigma), penicillin (100 units/ml) (Sigma)
and streptomycin (100 lg/ml) (Sigma). The cultures were
kept at 37 C in humidified atmosphere of 95 % air and
5 % CO2.
Drug Treatment
Sorafenib (Nexavar, BAY 43-9006) at the final concen-
trations 0.25, 0.5, 0.75, 1, 5 lM and quercetin (3,30,40,5,7-
pentahydroxyflavone) (Sigma) at the final concentrations
30 lM in the case of MOGGCCM and 50 lM in the case
of T98G were used in the experiments. The quercetin
concentrations were chosen on the basis of our earlier
studies conducted on both the cell lines (Jakubowicz-Gil
et al. 2010, 2011, 2013a). The drugs were dissolved in
dimethyl sulfoxide (DMSO, Sigma). The final concentra-
tion of DMSO in the culture medium did not exceed
0.01 %, which, as indicated in preliminary experiments,
did not influence cell viability and the expression of the
proteins studied. Two variants of drug treatment were
performed. In the first one, the cells were incubated only
with sorafenib for 24 or 48 h. In the second one, quercetin
and sorafenib were added to the culture medium at the
same time and incubated for 24 or 48 h. The control cells
were incubated with 0.01 % of DMSO.
Detection of Apoptosis and Necrosis
with Fluorochromes
For identification of apoptosis and necrosis, the cells were
stained with fluorescent dyes Hoechst 33342 (Sigma) and
propidium iodide (Sigma), respectively (Jankowska et al.
1997). The morphological analysis was performed under a
fluorescence microscope (Nikon E—800). Cells exhibiting
blue fluorescent nuclei (fragmented and/or with condensed
chromatin) were interpreted as apoptotic. Cells exhibiting
pink fluorescent nuclei were interpreted as necrotic. At
least 1,000 cells in randomly selected microscopic fields
were counted under the microscope. Each experiment was
performed in triplicate.
Detection of Acidic Vesicular Organelles with Acridine
Orange
Autophagy is a process of sequestrating cytoplasmic pro-
teins into the lytic compartment and is characterized by
formation and promotion of acidic vesicular organelles
(AVOs). Vital staining with 1 lg/ml of acridine orange
was performed for 15 min to detect AVOs in cells treated
with quercetin and/or sorafenib (Takeuchi et al. 2005).
Typical acridine orange-positive cells exhibiting granular
discretion of AVOs in the cytoplasm were interpreted as
autophagic. The morphological analysis was performed
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under a fluorescence microscope (Nikon E—800). At least
1,000 cells in randomly selected microscopic fields were
counted. Each experiment was performed in triplicate. The
percentage of autophagic cells was calculated as the
number of cells with AVOs versus the total number of
stained cells.
Detection of Apoptosis and Necrosis by Flow
Cytometry
The Annexin V-FITC apoptosis detection kit (Sigma) was
used for detection of apoptosis and necrosis by flow
cytometry. The samples were prepared according to the
manufacturer’s protocol. Briefly, the control and drug-
treated cells were incubated with 5 ll of Annexin V-FITC
and 10 ll of propidium iodide for 10 min. Immediately
after staining, the cells were analysed with the FacsCanto
instrument (Becton–Dickinson, San Jose, CA, USA). In
total, 30,000 events were acquired and analysed using
FacsDiva software. Cells that were in the early apoptotic
process were stained only by Annexin V-FITC; late
apoptotic cells were stained by both the fluorochromes.
Cells stained only by propidium iodide were interpreted as
necrotic. Live cells showed no staining by either propidium
iodide or Annexin V-FITC. Each experiment was per-
formed in triplicate.
Mitochondrial membrane potential
Fluorochrome 3,30-dihexyloxacarbocyanine iodide [DiOC6(3)]
was used for studying the changes in the mitochondrial mem-
brane potential (Dwm) in cells incubated with quercetin and
sorafenib. At low concentrations, the stain accumulates in
mitochondria. Loss of DiOC6(3) staining indicates disruption of
the mitochondrial inner transmembrane potential (Kim et al.
2008). The control and drug-treated cells were incubated with
fluorochrome at the final concentration 50 nM for 20 min at
37 C in the dark, washed three times with phosphate buffered
saline (PBS), and analysed with the FacsCanto instrument
(Becton–Dickinson, San Jose, CA, USA). In total, 30,000
events were acquired and analysed using FacsDiva software.
Each experiment was performed in triplicate. The results were
expressed as relative intensity of DiOC6(3) brightness.
Mitochondrial Fraction Isolation
A commercial isolation kit was used (Sigma) for isolation
of mitochondria. The samples were prepared according to
the manufacturer’s protocol. Briefly, after quercetin or/and
sorafenib treatment at the density of about 2 9 107, the
cells were trypsinised, centrifuged for 5 min (6009g) and
washed twice with PBS. The cell pellet was resuspended in
lysis buffer (Sigma), incubated for 5 min on ice and
centrifuged for 10 min (6009g). The supernatant was
transferred into a fresh tube and centrifuged at
11,0009g for 10 min. The pellet was resuspended in cell
lysis buffer and used for electrophoresis.
Isolation of the Cytosolic Fraction
After the quercetin and/or sorafenib treatment, the cells
were lysed in hot lauryl sulphate (SDS)-loading buffer
(125 mM Tris–HCl pH 6.8; 4 % SDS; 10 % glycerol;
100 mM dithiothreitol), boiled in water bath for 10 min
and centrifuged at 10,0009g for 10 min; next, the super-
natants were collected. The protein concentration was
determined by the Bradford method (Bradford 1976) and
samples of the supernatants containing 80 lg of proteins
were used for electrophoresis.
Immunoblotting
The cytoplasmic and mitochondrial samples were separated
by 10 % SDS-polyacrylamide gel electrophoresis (Laemmli
1970) and subsequently transferred onto an Immmobilon P
membrane (Sigma). Following the transfer, the membrane
was blocked with 3 % low-fat milk in PBS for 1 h and
incubated overnight with a mouse anti-Hsp72 monoclonal
antibody (SPA 810, StressGen) at the concentration 0.2 lg/
ml, anti-Hsp27 (SPA 800, StressGen) at the concentration
0.1 lg/ml, rabbit anti-LC3 (Sigma) at the concentration 2 lg/
ml, anti-beclin 1 antibody (Sigma) at the concentration 3 lg/
ml, anti-Ras (Santa Cruz Biotechnology) at the concentration
0.5 lg/ml, anti-Raf (Santa Cruz Biotechnology) at the con-
centration 0.5 lg/ml, and sheep anti-cytochrome c antibody
(Sigma) at the concentration 0.2 lg/ml. The membranes were
washed three times with PBS containing 0.05 % Triton X-100
(Sigma) for 10 min and incubated for 2 h with alkaline
phosphatase-conjugated goat anti-mouse, anti-sheep or anti-
rabbit secondary antibodies (Sigma). The membranes were
visualised with an alkaline phosphatase substrate (5-bromo-4-
chloro-3-indolylphosphate and nitro-blue tetrazolium,
Sigma) in a colour development buffer N,N-dimethylform-
amide (DMF, Sigma). The data were normalised relative to b-
actin (detected by mouse anti-b-actin antibodies at the con-
centration 0.5 lg/ml, Sigma).
The levels of protein expression were determined using
the Bio-Profil Bio-1D Windows Application V.99.03 pro-
gramme. The value was expressed as relative intensity of
band thickness, width and colour depth. Three independent
experiments were performed.
Caspase Activity Assay
Caspases are cysteine proteases that exist in normal con-
ditions as inactive pro-forms or zymogens. They are
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cleaved to the active form following induction of apoptosis.
The activity of caspases 3, 8 and 9 was estimated using a
SensoLyteAMC Caspase Substrate Sampler Kit (Ana-
Spec) in the control and drug-treated cells. Sample prepa-
ration and the enzymatic reaction were performed
according to the manufacturer’s protocol. The fluorescence
of 7-aminocoumarin (AMC) was monitored at Ex/Em =
354/442 nm in 96-well black microplates using a 2030
Multilabel Reader VictorTMx4 (Perkin Elmer).
Cell Transfection
The MOGGCCM and T98G cells at a density of 2 9 105
were seeded in a six-well tissue culture plate and incubated at
37 C in a CO2 incubator for 24 h until confluence reached
60–80 %. The cells were washed with a 3:1 DMEM:Ham’s
F-12 mixture without serum and antibiotics, and aspirated.
For each transfection, probes containing 2 ll of a specific
anti-Hsp27 or anti-Hsp72 small interfering RNA (siRNA)
duplex (Santa Cruz Biotech) and 2 ll of Transfection
Reagent (Santa Cruz Biotech) were prepared, overlaid onto
washed cells and incubated for 5 h at 37 C in a CO2 incu-
bator. After this time, the medium was enriched with a growth
medium containing 20 % of foetal bovine serum and 200 lg/
ml of antibiotics without removing the transfection mixture
and the cells were incubated for additional 18 h. Then the
medium was replaced by a fresh normal growth medium and
the transfected cells were used for further experiments. The
effectiveness of gene silencing was analysed at the protein
level by the immunoblotting technique.
Indirect Immunofluorescence
After the treatment with quercetin and/or sorafenib, the cells
were washed three times with PBS and fixed in 3.7 % para-
formaldehyde (Sigma) in PBS for 10 min. After extensive
washing with PBS, the cells were treated with 0.2 % Triton
X-100 (Sigma) for 7 min and then washed three times with
PBS, all at room temperature. Subsequently, a blocking step
of 30-min incubation in 5 % low-fat milk at room temperature
was included. Next, the cells were incubated with rabbit
antibody anti-beclin 1(Sigma) at a concentration of 30 lg/ml.
The primary antibodies were detected with fluorescein
(FITC)-conjugated anti-rabbit antibodies (Sigma).
Protein localisation in the cells was analysed using the
scanning head PASCAL5 (Zeiss). The fluorescent channel was
k = 488 nm. Three independent experiments were performed.
Over 100 cells were analysed in each experimental variant.
Statistical Analysis
The data are presented as mean ± standard deviation (SD).
The statistical evaluation was performed with a one-way
Anova test followed by Dunnett’s multiple comparison
test. P \ 0.05 was taken as the criterion of significance.
Results
Sensitivity of T98G and MOGGCCM Cells
to Sorafenib Treatment
To estimate the sensitivity of T98G and MOGGCCM cells
to the sorafenib treatment, a staining method with dyes
specific for apoptosis, necrosis and autophagy; i.e. Hoechst
33342, propidium iodide and acridine orange, respectively,
was employed (Fig. 1). Microscopic observations revealed
that sorafenib applied at the concentrations 0–5 lM to the
MOGGCCM culture medium for 24 h (Fig. 1a) had no
considerable effect on cell death. A significant increase in
the number of apoptotic cells was observed after 48 h of
incubation, reaching a maximum (5.6 %) at the concen-
tration 5 lM (Fig. 1c). Besides apoptosis, sorafenib initi-
ated necrosis at a level exceeding the percentage of
apoptotic cells. In the case of T98G, sorafenib applied to
the culture medium for 24 (Fig. 1b) and 48 h (Fig. 1d, h)
appeared to be a potent autophagy inducer. In the case of
24-h long incubation, sorafenib at the concentration 1 lM
initiated the process in 16 % of the cells. The longer
incubation time was even more effective. About 40 % of
cells treated with 0.75 or 1 lM of sorafenib exhibited
bright red vesicles at the edge of cells observed after
staining with acridine orange (Fig. 1h). The indirect
immunofluorescence technique revealed that the autophagy
marker beclin1 was localised at these vesicles (Fig. 1g).
The drug had no significant effect on induction of apoptosis
and necrosis in T98G cells.
Sensitivity of T98G and MOGGCCM Cells
to Combined Sorafenib and Quercetin Treatment
Based on the results described earlier, to examine the
combined effect of sorafenib with quercetin, the drug at the
concentration 0.75 lM applied to MOGGCCM cells for
24 h and T98G cells for 48 h was chosen. The incubation
of T98G cells with sorafenib at the concentration 0.75 lM
with increasing quercetin concentrations (0–50 lM) for
48 h revealed that such a combination mainly induced
programmed cell death. When the cells were treated
simultaneously with the combination of 50 lM of quer-
cetin and 0.75 lM of sorafenib, apoptosis was observed in
20 % of the cells, which was accompanied by autophagy in
25 % of the cells (Fig. 1f). When the MOGGCCM cells
were incubated with sorafenib (0.75) and quercetin
(30 lM) for 24 h, apoptosis was the most frequent (35 %)
(Fig. 1e). Co-incubation with sorafenib and flavonoid at the
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concentration 50 lM resulted in severe necrosis. The level
of autophagy was not significant.
Evaluation of Cell Death and Mitochondrial
Transmembrane Potential by Flow Cytometry
To confirm the reliability of the results obtained through
the microscopic observations, T98G cells treated with
quercetin (50 lM) and sorafenib (0.75 lM) for 48 h and
MOGGCCM cells treated with quercetin (30 lM) and so-
rafenib (0.75 lM) for 24 h separately as well as in com-
bination of both the drugs were analysed by flow cytometry
according to the type of cell death (apoptosis or necrosis)
and the mitochondrial membrane potential (Balasubrama-
nian and Schroit 2003; Ghobrial et al. 2005).
The incubation of the cells with quercetin confirmed that
the flavonoid induced mainly necrosis in the MOGGCCM
(Table 1a) and had no such effect on the T98G cells
(Table 1b). Sorafenib alone induced mainly late apoptosis
in both the cell lines at the level of 6 %. When quercetin
and sorafenib were added to the culture medium together,
late apoptosis was frequently observed in the MOGGCCM
cells (6.9 %). In the case of the T98G cells, early apoptosis
was predominant and reached about 6.3 %.
It is known that a decreased mitochondrial membrane





Fig. 1 The level of apoptosis,
necrosis and autophagy
induction in the anaplastic
astrocytoma MOGGCCM (a, c,
e) and the glioblastoma
multiforme T98G (b, d,
f–h) cell lines treated only with
sorafenib (0–5 lM) for 24 h (a,
b) or 48 h (c, d) and sorafenib
in combination with quercetin
(e, f) stained with Hoechst
33342, propidium iodide and
acridine orange, C-control cells
(without sorafenib or quercetin),
*P \ 0.05 compared to control
g—localisation of the
autophagy marker protein beclin
1 in T98G cells after treatment
with sorafenib (0.75 lM) for
48 h (pointed by arrows)
h—autophagic vacuoles in
T98G cells stained with acridine
orange after 48-h-long
incubation with sorafenib
(0.75 lM) (pointed by arrows)
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(Ghobrial et al. 2005). In our experiments, both quercetin
and sorafenib applied alone or in combination decreased
this potential in the T98G and MOGGCCM cells (Fig. 2).
In the glioblastoma multiforme cells, the lowermost value
was observed after simultaneous drug treatment. In the case
of MOGGCCM cells, sorafenib alone or in combination
with quercetin decreased the mitochondrial membrane
potential most effectively, in comparison to the control. An
increase in this parameter was observed only after incu-
bation with quercetin.
The Effect of Sorafenib and Quercetin on Expression
of Marker Proteins
Using the immunoblot technique, we studied the effect of
sorafenib and quercetin, applied separately or in combi-
nations, on the level of the pro-apoptotic cytochrome c
expression (in the cytoplasmic and mitochondrial fraction),
anti-apoptotic molecular chaperones Hsp27 and Hsp72,
pro-survival Ras, Raf, and pro-autophagic beclin1and LC3
in the MOGGCCM (Fig. 3) and T98G (Fig. 4) cells.
Additionally, we analysed fluorimetrically the activity of
caspases 3, 8 and 9.
Quantitative and qualitative analyses of the immuno-
blots revealed that quercetin and sorafenib applied alone or
in combination inhibited the expression of Hsp72, Hsp27,
Ras and Raf in all the experimental variants in both the cell
lines. The drugs were also very effective in decreasing the
level of cytochrome c in the mitochondrial fraction, which
was accompanied by increased accumulation of the protein
in the cytoplasm. In the case of beclin 1, quercetin and
sorafenib had no significant effect on the protein expres-
sion in the MOGGCCM cells and its level was similar to
the control one in all the experimental variants. In the
T98G cells, overexpression of beclin 1 was observed after
separate sorafenib treatment and after sorafenib with
quercetin. In other experimental variants, the level of be-
clin 1 was similar to the control. Conversion of LC3I into
its smaller form LC3II is the hallmark of autophagy.
Similar to beclin1, increased level of LC3II was observed
only in T98G cells after separate sorafenib treatment and in
combination with quercetin. In the case of caspases,
quercetin and sorafenib applied in combination (but not in
the separate application) increased the activity of caspase 3
and caspase 9 in the MOGGCCM cells. In the T98G cells,
elevated activity of the enzymes was observed after sepa-
rate quercetin treatment and when both the drugs were
added at the same time. Sorafenib and quercetin applied
alone or in combination had no effect on caspase 8 activity
in the MOGGCCM and T98G cells.
Blocking the Hsp27 and Hsp72 Expression in T98G
and MOGGCCM Cells
To block the expression of Hsp27 and Hsp72, the T98G
and MOGGCCM cells were transfected with specific siR-
NA. Western blot analysis revealed that the silencing was
very effective at the protein level (Fig. 5) and no expres-
sion of Hsps was observed even after subsequent quercetin
and/or sorafenib treatment. Incubation of the cells either
with only the transfection reagent or with only siRNAs had
no effect on the expression of heat shock proteins.
Apoptosis, Autophagy and Necrosis Induction
in Transfected Cells
The effect of sorafenib and quercetin on cell death induc-
tion in the T98G and MOGGCCM (Fig. 6) cells with
blocked Hsp expression was studied by means of micro-
scopic observations (Fig. 6a, b) and flow cytometry
(Fig. 6c, d). Both the methods revealed that quercetin and
sorafenib were extremely effective in cell death induction
in transfected MOGGCCM and T98G cells, especially
Table 1 The effect of quercetin (Q) and sorafenib (S) on apoptosis
and necrosis induction in MOGGCCM (a) and T98G (b) cells ana-








Control 0.2 ± 0.09 0.2 ± 0.2 0.2 ± 0.07
Q (30 lM) 48.8 ± 5.3* 0.5 ± 0.14 0.2 ± 0.07
S (0.75 lM) 0.7 ± 0.4 0.3 ± 0.07 6.7 ± 0.35*
SQ 0.5 ± 0.07 1.3 ± 0.77 6.9 ± 0.29*
b
Control 0.3 ± 0.07 0.2 ± 0.07 0.2 ± 0.07
Q (50 lM) 2.7 ± 0.4 8.2 ± 1.2* 8.6 ± 0.07*
S (0.75 lM) 0.1 ± 0.07 2.7 ± 0.96 6.3 ± 0.29*
SQ 0.3 ± 0.5 6.3 ± 0.77* 4.8 ± 0.4*
* P \ 0.05
Fig. 2 The mitochondrial membrane potential in MOGGCCM and
T98G cells stained with DiOC6(3), incubated separately with
quercetin (Q) and sorafenib (S) or in combination of both the drugs
(SQ) for 24 h (MOGGCCM) or 48 h (T98G) and analysed by flow
cytometry, C control cells, *P \ 0.05 compared to control
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when both the drugs were added to the culture medium
simultaneously.
Microscopic observations of T98G cells with dimin-
ished Hsp27 expression showed over 60 % of apoptotic
cells after the quercetin treatment, 15 % after the sorafenib
incubation and 40 % after the simultaneous drug applica-
tion. In the case of reduced Hsp72 expression, sorafenib
applied in combination with the flavonoid appeared to be
the most effective in apoptosis induction, as it initiated
programmed cell death in about 50 % of cells. Sorafenib
itself appeared to be the least effective in induction of
apoptosis (19 %) but still the result was significant. In the
MOGGCCM cells, blocking of the Hsp27 or Hsp72
expression resulted in an increased number of apoptotic
cells after the simultaneous sorafenib and quercetin treat-
ment (about 30 %). Quercetin was less effective but still
the effect was significant. Interestingly, blocking of the
Hsp27 or Hsp72 expression did not increase the sensitivity













beclin 1 (e), LC3 (f), Ras
(g) and Raf (h) expression with
representative blots and the
activity of caspase 3, 8, 9
(i) after sorafenib (S) and
quercetin (Q) treatment for 24 h
in MOGGCCM. The data were
normalised relative to b-actin
(not shown). C control cells, SQ
simultaneous drug treatment,
* P \ 0.05 compared to control
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In comparison to the microscopic observations, flow
cytometry appeared to be a more sensitive method for
detection of apoptosis in MOGGCCM and T98G cells
transfected with specific siRNA. Apoptosis was observed
in over 90 % of the cells, irrespective of the type of cells,
type of blocked protein and subsequent drug treatment. The
method also allowed distinguishing between early and late
apoptosis. As shown in Fig. 6c and d, apoptosis after the
quercetin and/or sorafenib treatment was detected mainly
in the early stage of the process in both the cell lines.
Our results indicate that inhibition of Hsp72 or Hsp27







Fig. 4 The level of Hsp27 (a), Hsp72 (b), cytochrome c (c cytoplas-
mic, d mitochondrial fraction), beclin 1 (e), LC3 (f), Ras (g) and Raf
(h) expression with representative blots and the activity of caspase 3,
8, 9 (i) after sorafenib (S) and quercetin (Q) treatment for 48 h in
T98G. The data were normalised relative to b-actin (not shown).
C control cells, SQ simultaneous drug treatment, *P \ 0.05 compared
to control




Fig. 5 The level of Hsp27 and
Hsp72 expression in T98G (a, c) and
MOGGCCM (b, d) cells after
transfection with specific anti-
Hsp27 (a, b) or anti-Hsp72 (c,
d) siRNA (si27 and si72,
respectively) and subsequent
quercetin (Q) and sorafenib
(S) treatment, estimated by
immunoblotting. T98G cells were
incubated with 50 lM of quercetin
and 0.75 lM sorafenib, while
MOGGCCM cells with 30 lM
(Q30) of quercetin and 0.75 lM of
sorafenib. Protein level was
normalised according to b-actin
expression. C control, TR
transfection reagent, TRsi
transfection reagent with specific
siRNA, SQ simultaneous quercetin





Fig. 6 The effect of quercetin
(Q) and sorafenib (S) on
apoptosis, necrosis and
autophagy induction in
MOGGCCM (a, c, e) and T98G
(b, d, f) cells transfected with
specific siRNA anti-Hsp27
(si27) and anti-Hsp72 (si72).
C control, TR transfection
reagent, a, b cell death
estimated by microscopic
observation of cells stained with
Hoechst 33342, propidium
iodide, acridine orange, c,
d apoptosis and necrosis
induction estimated by flow
cytometry with the Annexin
V-FITC detection kit, e, f the
mitochondrial membrane
potential studied by flow
cytometry after staining with
DiOC6(3), *P \ 0.05 compared
to control
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autophagy induction upon the quercetin and sorafenib
treatment.
The Effect of Quercetin and Sorafenib on the
Mitochondrial Membrane Potential in Transfected Cells
The flow cytometry analysis of DiOC6(3)-stained MOG-
GCCM and T98G cells with blocked Hsp27 and Hsp72
expression revealed that quercetin and sorafenib applied
alone or in combination significantly decreased the mito-
chondrial membrane potential. As shown in Fig. 6e, such
an inhibitory effect in the MOGGCCM cells was the most
efficient after the quercetin treatment, while in the T98G
cells (Fig. 6f)—after the simultaneous drug incubation.
The Effect of Sorafenib and Quercetin on Marker
Protein Expression in Transfected Cells
Quantitative and qualitative analyses of immunoblots
with proteins isolated from the MOGGCCM (Fig. 7) and
T98G (Fig. 8) cells with blocked Hsp27 or Hsp72
expression revealed that quercetin and sorafenib applied
alone or in combination increased the level of pro-apop-





Fig. 7 The level of cytochrome
c (a cytoplasmic,
b mitochondrial fraction), Ras
(c), Raf (d), LC3 (e) and beclin
1 (f) expression with
representative blots and the
activity of caspase 3, 8, 9
(f) after sorafenib (S) and
quercetin (Q) treatment for 24 h
in MOGGCCM cells transfected
with specific siRNA anti-Hsp27
(si27) and anti-Hsp72 (si72).
The data were normalised
relative to b-actin (not shown).
C control cells, SQ simultaneous
drug treatment, si27 or si72
specific siRNA blocking Hsp27
or Hsp72 expression, TR
transfection reagent, TRsi
transfection reagent with
specific siRNA *P \ 0.05
compared to control
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accompanied by a decreased level of the protein in the
mitochondrion. Neither of the drugs had an effect on the
beclin 1 expression and the level of the protein was
similar to the control. No conversion of LC3I into its
smaller form LC3II was also observed. Quercetin and
sorafenib applied alone or in combination inhibited the
expression of Ras and Raf in both the cell lines. In the
case of caspases, both the drugs applied alone or in
combination increased the activity of capase 3 and cas-
pase 9 in T98G and MOGGCCM cells with blocked Hsp
expression. Sorafenib and quercetin did not change the





Fig. 8 The level of cytochrome c (a cytoplasmic, b mitochondrial
fraction), Ras (c), Raf (d), LC3 (e) and beclin 1 (f) expression with
representative blots and the activity of caspase 3, 8, 9 (g) after
sorafenib (S) and quercetin (Q) treatment for 48 h in T98G cells
transfected with specific siRNA anti-Hsp27 (si27) and anti-Hsp72
(si72). The data were normalised relative to b-actin (not shown).
C control cells, SQ simultaneous drug treatment, si27 or si72 specific
siRNA blocking Hsp27 or Hsp72 expression, TR transfection reagent,
TRsi transfection reagent with specific siRNA, *P \ 0.05 compared
to control
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Discussion
In malignant gliomas, several mechanisms responsible for
programmed cell death induction, like apoptosis or autoph-
agy, are blocked while molecular chaperones promoting cell
survival are overexpressed (Ghobrial et al. 2005; Ohgaki and
Kleihues 2005; Omuro et al. 2007). Recent publications
indicate that a majority of gliomas display upregulated Raf
kinase (the first effector kinase downstream of Ras), which
is essential for activation of the mitogen-activated protein
pathway Ras–Raf–MEK–ERK. The upregulation of this
signalling cascade has been proven to take part in amplifi-
cation of mitogenic stimuli and promotion of cellular pro-
liferation of gliomas (Lo 2010). Such observations provide a
rationale for attempting to disrupt this pathway as a good
candidate in anticancer strategy. Recently, a number of
specific inhibitors have been developed. Among these, so-
rafenib seems to have a pivotal role. It has been demon-
strated in various tumour cell lines that sorafenib induced
mitochondrial damage manifested by cytochrome c release
into the cytosol, caspase 9 and 3 activation, and in conse-
quence, apoptosis mediated through an intrinsic pathway
(Huang et al. 2010; Rahmani et al. 2007; Yu et al. 2006). On
the other hand, other experiments showed that apoptosis
after sorafenib treatment was correlated with an external
pathway with caspase 8 activation (Park et al. 2010). There
are also some reports indicating that sorafenib also induced
autophagy (Sieglin et al. 2010). Considering such multiple
effects of sorafenib on induction of programmed cell death
and different mechanisms activated within cells, we decided
to evaluate the type of cell death that will be predominant in
human glioblastoma multiforme (T98G) and anaplastic
astrocytoma (MOGGCCM) cells. Our experiments showed
that in anaplastic astrocytoma, the drug induced mainly
apoptosis, but at a level only slightly higher than that
observed in non-treated, control cells. The process was ini-
tiated through a mitochondrial pathway. In the case of
glioblastoma multiforme cells, sorafenib appeared to be a
very effective autophagy inducer. At the molecular level,
this was correlated with the increased conversion of LC3I
form of LC3 into LC3II—the first mammalian protein in-
dentified that specifically associates with autophagosome
membranes. Therefore, the cleavage of LC3I into LC3II is
the hallmark of autophagy (Kabeya et al. 2000). Increased
beclin 1 expression, a critical component involved in auto-
phagosome formation in the early stage of autophagy, was
also observed. It has also been shown that activation of
caspase 3 inhibits autophagosome formation and may block
beclin 1 activity or even cleave the protein (Luo and Ru-
binsztein 2010; Pirtoli et al. 2009; Wang 2008; Wirawan
et al. 2010). In the T98G cells, the activity of caspase 3 was
not significant, in contrast to the anaplastic astrocytoma
cells, where the activity of the enzyme was increased.
The very interesting morphology of autophagic T98G
cells should be emphasized. Death vesicles were concen-
trated at the edges of cells but not dispersed throughout the
cytoplasm. The authenticity of the peripheral vacuoles as
autophagic ones was confirmed by localisation of beclin 1
within them. The cause of such an unusual distribution is
unknown.
Natural bioactive compounds may act in synergy with
drugs used in anticancer therapy (Braganhol et al. 2006;
Jakubowicz-Gil et al. 2010, 2011, 2013a; Ramos 2007;
Russo 2007; Schu¨ltke et al. 2005). In the present pioneer
study, the use of the combination of sorafenib with quer-
cetin resulted in an effective cell type-specific induction of
apoptosis and autophagy. After the treatment with both the
drugs, apoptosis was most frequent in the anaplastic
astrocytoma cells. The percentage of dead cells was higher
than that observed after the single sorafenib applications.
At the molecular level, apoptosis was mediated by an
intrinsic pathway. In the case of T98G cells treated with
sorafenib and quercetin, the level of dead cells was com-
parable with that observed after the separate sorafenib
treatment; and simultaneous incubation with both the drugs
induced both apoptosis and autophagy. Keeping in mind
that quercetin induces mainly apoptosis while sorafenib
mainly autophagy, it seems that these drugs initiated dif-
ferent pathways in the glioblastoma multiforme cell line.
As described earlier, the balance between caspase 3 and
beclin 1 may have a critical role in such diversity.
In our study, sorafenib as well as quercetin applied alone
or in combination decreased the level of Ras and Raf
expression in the MOGGCCM and T98G cells, thereby
upregulating the Ras–Raf–MEK–ERK pathway. The level
of inhibition was similar in both the cell lines, irrespective of
the drug precedence and concentration. This indicates that
decreased signal transmission through the Ras–Raf–MEK–
ERK cascade increases the sensitivity of glioma cells to
death upon sorafenib and quercetin treatment and stimulates
apoptosis and autophagy induction with the same effect.
Heat shock proteins are molecular chaperones whose
activity protects cells against death. They are engaged in
preventing cytochrome c release, mitochondrial membrane
permeabilization, maturation of procaspase 9 and caspase 3
activation. Depletion of Hsp27 and Hsp72 severely decrea-
ses degradation of misfolded proteins (Stetler et al. 2010;
Turturici et al. 2011). In cancer cells, where the level of heat
shock proteins is abnormally high, these molecular chaper-
ones act as negative prognostic markers. It was also
observed that the expression of the proteins rose with the
grade of the tumour and that they might participate in
oncogenesis. Therefore, inhibition of heat shock protein
expression has become a novel strategy for cancer therapy
(Garrido et al. 2006; Graner et al. 2007; Jakubowicz-Gil
et al. 2013b; Sreedhar and Csermley 2007). In our
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experiments, both sorafenib and quercetin partially inhibited
Hsp27 and Hsp72 expression in the T98G and MOGGCCM
cells. Additional block of their expression by specific siRNA
showed very good predisposition of the combination of the
drugs to induce apoptosis in transfected cells. This type of
programmed cell death was detected in about 90 % of the
cell population, where most cells were in the early stage of
the process. As revealed by the molecular analysis, apoptosis
in the transfected cells was mediated by an intrinsic signal.
Blocking of Hsp27 and Hsp72 expression in the T98G
and MOGGCCM cells did not increase sensitivity to
autophagy induction upon sorafenib and quercetin treatment.
It is known that therapeutically increased autophagy could
represent an alternative way to destroy cancer cells. This
would be beneficial in the light of recent investigations, as
gliomas naturally resist apoptosis. On the other hand, many
studies demonstrate that autophagy represents a protective
mechanism helping cancer cells to get rid of toxic particles
and, in consequence, to increase their survival. In the light of
these observations, redirecting cancer cells to enter the
apoptotic pathway would be beneficial (Garcia-Arencibia
et al. 2010; Lefranc and Kiss 2006; Lin et al. 2012). Elim-
inating Hsp expression by siRNA significantly increased the
sensitivity of the T98G cell line to induction of apoptosis but
not autophagy. This may be explained by the fact that Hsps
are very effective caspase 3 inhibitors. Elimination of these
molecular chaperones from cells does not result in blocking
caspase 3 activity, which in turn may decrease the level of
beclin 1 and block autophagy in consequence.
In summary, we demonstrated for the first time that
sorafenib applied in combination with quercetin is a very
potent programmed cell inducer in glioma multiforme
T98G and anaplastic astrocytoma MOGGCCM cells but
the type of death, apoptosis or autophagy, is cell type and
drug precedence specific. Our results indicate that blocking
of Hsp27 and Hsp72 expression makes T98G and MOG-
GCCM cells extremely vulnerable to apoptosis induction
upon sorafenib and quercetin treatment and that pro-
grammed cell death is initiated by an internal signal. They
also confirm that molecular chaperones are responsible for
glioma cell resistance to programmed cell death and that
the natural bioactive compound acts in synergy with anti-
cancer drugs. We demonstrated that sorafenib administered
with quercetin seems to be a potent and promising com-
bination that might be useful in glioma therapy.
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